Evidence map›Paper›PMID 40881755›Full record

ArticleWorld journal of transplantation2025

Major adverse cardiovascular events and hyperuricemia as an effect-modifying factor in kidney transplant recipients.

Elizabete Junk, Lilian Tzivian, Inese Folkmane, Kristofs Folkmanis, Janis Jushinskis, Gunta Strazda, Valdis Folkmanis, Viktorija Kuzema, Aivars Petersons

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elizabete JunkDepartment of Internal Diseases, St. Bonifatius Hospital Lingen, Lingen 49808, Germany.
Lilian TzivianFaculty of Medicine and Life Sciences, University of Latvia, Riga LV-1004, Latvia.
Inese FolkmaneFaculty of Medicine and Life Sciences, University of Latvia, Riga LV-1004, Latvia.
Kristofs FolkmanisFaculty of Medicine and Life Sciences, University of Latvia, Riga LV-1004, Latvia.
Janis JushinskisCentre of Transplantation, Pauls Stradiņš Clinical University Hospital, Riga LV-1002, Latvia.
Gunta StrazdaFaculty of Medicine and Life Sciences, University of Latvia, Riga LV-1004, Latvia.
Valdis FolkmanisFaculty of Medicine and Life Sciences, University of Latvia, Riga LV-1004, Latvia.
Viktorija KuzemaCentre of Nephrology, Pauls Stradiņš Clinical University Hospital, Riga LV-1002, Latvia.
Aivars PetersonsFaculty of Medicine, Riga Stradins University, Riga LV-1007, Latvia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMajor adverse cardiovascular (CV) events (MACEs) are the primary cause of morbidity and mortality in kidney transplantation (KT) recipients. The risk for MACEs is impacted by an array of traditional and transplant-related non-traditional CV risk factors.

aimTo investigate the association between potential CV risk factors related to KT and MACEs, and their potential modification by hyperuricemia (HU).

methodsThe relationship between CV risk factors related to KT and MACEs was examined in a cohort of 545 patients who underwent transplantation between 2008 and 2019. The mean age of patients at KT was 55.0 years ± 14.2 years (range 15.0-89.0 years). Univariate and multivariate logistic regression models were constructed to identify risk factors influencing MACEs. To explore the potential effect modification by uric acid (UA), patients were categorized into groups based on UA levels: (1) Low (< 356 μmol/L); (2) Normal (356-416 μmol/L); (3) High (416-475 μmol/L); and (4) Very high (> 475 μmol/L).

resultsMACEs occurred in 145 of 545 (26.6%) KT recipients. The most prevalent comorbidities were hypertension (87%), dyslipidemia (78%), secondary hyperparathyroidism (68%), HU (63%) and anemia (33%). In the multivariate logistic regression model, the most significant factors associated with MACEs were previous CV events [odds ratio (OR) = 70.6, 95%CI: 24.9-200.1], left ventricular hypertrophy (LVH) (OR = 12.6, 95%CI: 2.7- 58.3), HU treatment (OR = 4.3, 95%CI: 2.4-7.6), and anemia (OR = 5.3, 95%CI: 2.9-9.8). Effect modification by the presence of HU revealed that independent factors associated with MACEs were age (OR = 1.03, 95%CI: 1.0-1.1), previous CV events (OR = 41.7, 95%CI: 13.6-127.6), LVH (OR = 15.3, 95%CI: 2.0-116.6), HU treatment (OR = 2.5, 95%CI: 1.3-4.6) and anemia (OR = 5.4, 95%CI: 2.8-10.5). Effect modification by UA levels dichotomized at 475 μmol/L (very high level of UA) revealed that HU treatment was not associated with MACEs in groups with or without very high UA levels.

conclusionA very high level of UA was observed to act as an effect-modifying factor for MACEs, especially when combined with other risk factors such as age, previous CV events, LVH, and anemia.

Indexed as

Cardiovascular riskEffect modification by hyperuricemiaHyperuricemiaHyperuricemia treatmentKidney transplantationMajor adverse cardiovascular eventsUric acid

Identifiers

PMID40881755
PMCPMC12038604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.